Most people have heard of GLP-1 receptor agonists by now. These compounds mimic a gut hormone called glucagon-like peptide-1, which helps the body regulate blood sugar and appetite. Nearly every approved therapy that works through this receptor is a peptide, meaning it is made of amino acid chains and must be injected because the digestive system would break it down if swallowed.
Scientists have long been interested in finding small molecules that can do the same job through a pill. One candidate, a compound called danuglipron, showed real promise in clinical trials. It activated the GLP-1 receptor, reduced body weight in study participants, and improved blood sugar control. But it also came with a short duration of action, gastrointestinal side effects, and a reported case of drug-induced liver injury. Those problems were serious enough that trials were discontinued.
A paper published in Bioorganic Chemistry describes a new attempt to build on what danuglipron got right while addressing what went wrong. The researchers used a strategy called prodrug design, chemically modifying the original compound so that it converts to its active form gradually inside the body. The early lab results are cautiously encouraging, though the authors are clear that real-world testing in animals and humans has not yet happened.
What a prodrug actually is
A prodrug is an inactive or weakly active version of a compound that the body converts into the real active molecule after it is absorbed. Think of it like a time-release capsule built into the chemistry of the molecule itself rather than into a coating on a tablet.
The conversion usually happens through natural enzymes in the blood or tissues. By controlling how quickly that conversion happens, chemists can in theory extend how long a drug stays active, smooth out peaks and troughs in blood concentration, and sometimes reduce the burden on the liver by slowing initial metabolism.
This is not a new idea in pharmacology. Many widely used medications are prodrugs. What is new in this study is applying the prodrug concept specifically to small-molecule GLP-1 receptor agonists, a class that has had a difficult time making it through clinical development.
How the researchers designed the new compounds
The team took danuglipron as their starting point and synthesized a series of chemically modified versions. Two broad categories of modifications were explored: acid analogs and ester analogs. Both types involved swapping out specific chemical groups on the original scaffold or adding new ones to change how the molecule behaves in the body.
Acid forms of the compounds were tested first for basic receptor activity. The researchers found that several acid analogs retained activity comparable to the original compound and to tirzepatide, a peptide-based dual receptor agonist used as a benchmark. This confirmed that the core structure was still capable of engaging the GLP-1 receptor even after modification.
The ester analogs were the more experimental category. Esters are chemical forms that are generally less active on their own but can be cleaved by enzymes in the blood, converting into the corresponding acid form over time. The question was whether this conversion would happen in a controlled and sustained way, or too quickly, or not at all.
What the lab tests showed
The researchers focused particular attention on one ester compound, labeled compound 4 in the paper. When they added it to human plasma in laboratory conditions, mass spectrometry confirmed that it gradually converted into its active acid metabolite, labeled compound 4a.
Crucially, the conversion was not instantaneous. It happened over time, which is exactly what a prodrug approach is designed to achieve. Follow-up activity assays confirmed that compound 4a, once formed, was indeed active at the GLP-1 receptor.
This two-step confirmation, first that the conversion happens at a measurable rate and second that the resulting metabolite is biologically active, is the minimum evidence needed to call something a viable prodrug candidate. The authors describe these findings as suggesting the ester approach might represent a useful strategy for extending the pharmacokinetic profile of small-molecule GLP-1R agonists.
What pharmacokinetics means and why it matters here
Pharmacokinetics is the study of how a compound moves through the body: how fast it is absorbed, how it is distributed to tissues, how it is broken down, and how it is eliminated. A compound with poor pharmacokinetics might spike to high concentrations quickly and then vanish, which can cause side effects at the peak and offer no benefit once levels drop.
Danuglipron's short duration of action was one of the reasons it required multiple daily doses. The researchers hypothesize that an ester prodrug version, converting slowly to its active form in plasma, could provide a more sustained exposure without those sharp peaks. A flatter, longer exposure profile is often associated with fewer gastrointestinal side effects in this class of compounds, although that has not been tested here.
The liver injury concern is also relevant to pharmacokinetics. When a compound is absorbed rapidly and reaches high concentrations in the liver early on, the risk of liver-related toxicity can increase. A prodrug that releases its active form more slowly might reduce that burden, though the authors are careful to note this remains a hypothesis requiring dedicated toxicology studies.
Limitations the researchers acknowledged
The paper is unusually candid about what it does and does not prove. All of the key experiments were conducted in vitro, meaning in laboratory vessels using human plasma and cell-based assays rather than in living animals or people. The authors explicitly state that their hypotheses about sustained systemic exposure and potential safety advantages require further validation through appropriate in vivo pharmacokinetic and toxicological studies.
In vitro to in vivo translation is notoriously difficult in this field. A compound can behave beautifully in a test tube and then convert too quickly, too slowly, or unevenly once inside a living system with competing enzymes, varying pH across different tissues, and immune responses. None of that complexity is captured in the current data.
The study also does not address oral bioavailability directly. One of the main goals for small-molecule GLP-1R agonists is to create an effective oral therapy, but demonstrating that a compound survives digestion and reaches the bloodstream intact requires animal studies that have not yet been reported for these new analogs.
Where this fits in the broader research landscape
The GLP-1 receptor remains one of the most actively studied targets in metabolic medicine. Peptide-based therapies have proven effective in clinical practice, but their need for injection, cost, and supply limitations have driven interest in oral small-molecule alternatives for over a decade.
Danuglipron was one of the most advanced small-molecule GLP-1R agonist programs before its discontinuation, which made its failure a significant setback for the field. Research like this recent Bioorganic Chemistry paper represents the next phase: learning from that failure and asking whether chemical redesign can overcome its specific weaknesses.
The prodrug strategy is one of several approaches being explored across the literature. Others include altering the metabolic pathways the compound uses, co-formulation with absorption enhancers, and entirely different chemical scaffolds. Early-stage data like this study contributes to a growing body of knowledge about what structural features might make a small-molecule GLP-1R agonist both active and tolerable, even if clinical answers are still years away.
